30Jan 2023
Cardiovascular outcomes trial data from EMPA‐REG OUTCOME, CAROLINA, and CARMELINA: assessment of a novel staging system for type 2 diabetes

Cardiovascular outcomes trial data from EMPA‐REG OUTCOME, CAROLINA, and CARMELINA: assessment of a novel staging system for type 2 diabetes

The Diabetes Staging System (DSS), a novel disease staging system similar to those used in oncology and designed to improve physician/patient communication and diabetes management, was applied to three large type 2 diabetes (T2D) cardiovascular (CV) outcome trials to assess if increasing DSS stage was associated with higher rates of all‐cause mortality (ACM) and/or CV death. Based on the study findings, applying the DSS across T2D clinical trial populations with different CV risks revealed a significantly increased risk for ACM and CV death with a higher DSS stage. The DSS may benefit from assessment in other T2D populations and with the evaluation of the impact of additional outcomes, such as heart failure.

  • #endo-diabetology

Like

Save

Share